vs
AMERICAN SHARED HOSPITAL SERVICES（AMS）与CASTLE BIOSCIENCES INC（CSTL）财务数据对比。点击上方公司名可切换其他公司
CASTLE BIOSCIENCES INC的季度营收约是AMERICAN SHARED HOSPITAL SERVICES的11.3倍（$87.0M vs $7.7M）。CASTLE BIOSCIENCES INC同比增速更快（0.8% vs -14.8%）。CASTLE BIOSCIENCES INC自由现金流更多（$19.7M vs $-2.7M）。过去两年AMERICAN SHARED HOSPITAL SERVICES的营收复合增速更高（21.7% vs 9.2%）
美国共享医院服务公司为医疗机构提供放射治疗、立体定向放射外科及诊断成像设备的整体外包解决方案，免除医院高昂的前期资本投入，主要业务覆盖北美，同时服务拉美及部分亚太地区的公立、私立医院客户。
Castle Biosciences是一家处于商业阶段的诊断企业，专注于开发和商业化针对黑色素瘤等皮肤癌及罕见病的专利临床诊断检测产品，主要服务美国医疗市场，聚焦未被满足的精准诊断需求领域，辅助临床医生制定治疗决策。
AMS vs CSTL — 直观对比
营收规模更大
CSTL
是对方的11.3倍
$7.7M
营收增速更快
CSTL
高出15.6%
-14.8%
自由现金流更多
CSTL
多$22.4M
$-2.7M
两年增速更快
AMS
近两年复合增速
9.2%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $7.7M | $87.0M |
| 净利润 | $-631.0K | — |
| 毛利率 | 11.7% | 79.0% |
| 营业利润率 | -18.1% | -4.4% |
| 净利率 | -8.2% | — |
| 营收同比 | -14.8% | 0.8% |
| 净利润同比 | 52.5% | — |
| 每股收益（稀释后） | $-0.09 | $-0.06 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMSCSTL
| Q4 25 | $7.7M | $87.0M | ||
| Q3 25 | $7.2M | $83.0M | ||
| Q2 25 | $7.1M | $86.2M | ||
| Q1 25 | $6.1M | $88.0M | ||
| Q4 24 | $9.1M | $86.3M | ||
| Q3 24 | $7.0M | $85.8M | ||
| Q2 24 | $7.1M | $87.0M | ||
| Q1 24 | $5.2M | $73.0M |
净利润AMSCSTL
| Q4 25 | $-631.0K | — | ||
| Q3 25 | $-17.0K | $-501.0K | ||
| Q2 25 | $-280.0K | $4.5M | ||
| Q1 25 | $-625.0K | $-25.8M | ||
| Q4 24 | $-1.3M | — | ||
| Q3 24 | $-207.0K | $2.3M | ||
| Q2 24 | $3.6M | $8.9M | ||
| Q1 24 | $119.0K | $-2.5M |
毛利率AMSCSTL
| Q4 25 | 11.7% | 79.0% | ||
| Q3 25 | 22.1% | 77.5% | ||
| Q2 25 | 23.1% | 79.5% | ||
| Q1 25 | 15.4% | 81.4% | ||
| Q4 24 | 35.3% | 81.3% | ||
| Q3 24 | 19.6% | 81.8% | ||
| Q2 24 | 35.0% | 83.3% | ||
| Q1 24 | 41.1% | 81.0% |
营业利润率AMSCSTL
| Q4 25 | -18.1% | -4.4% | ||
| Q3 25 | -4.8% | -8.2% | ||
| Q2 25 | -7.7% | -4.9% | ||
| Q1 25 | -21.3% | -31.7% | ||
| Q4 24 | -20.2% | 4.7% | ||
| Q3 24 | -12.7% | 5.9% | ||
| Q2 24 | -0.0% | 5.8% | ||
| Q1 24 | -1.6% | -7.5% |
净利率AMSCSTL
| Q4 25 | -8.2% | — | ||
| Q3 25 | -0.2% | -0.6% | ||
| Q2 25 | -4.0% | 5.2% | ||
| Q1 25 | -10.2% | -29.4% | ||
| Q4 24 | -14.6% | — | ||
| Q3 24 | -3.0% | 2.6% | ||
| Q2 24 | 51.0% | 10.3% | ||
| Q1 24 | 2.3% | -3.5% |
每股收益（稀释后）AMSCSTL
| Q4 25 | $-0.09 | $-0.06 | ||
| Q3 25 | $0.00 | $-0.02 | ||
| Q2 25 | $-0.04 | $0.15 | ||
| Q1 25 | $-0.10 | $-0.90 | ||
| Q4 24 | $-0.21 | $0.32 | ||
| Q3 24 | $-0.03 | $0.08 | ||
| Q2 24 | $0.55 | $0.31 | ||
| Q1 24 | $0.02 | $-0.09 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $3.5M | $299.5M |
| 总债务越低越好 | $17.4M | $10.1M |
| 股东权益账面价值 | $24.0M | $470.9M |
| 总资产 | $55.5M | $578.6M |
| 负债/权益比越低杠杆越低 | 0.72× | 0.02× |
8季度趋势，按日历期对齐
现金及短期投资AMSCSTL
| Q4 25 | $3.5M | $299.5M | ||
| Q3 25 | $5.1M | $287.5M | ||
| Q2 25 | $11.1M | $275.9M | ||
| Q1 25 | $11.2M | $275.2M | ||
| Q4 24 | $11.0M | $293.1M | ||
| Q3 24 | $13.8M | $95.0M | ||
| Q2 24 | $14.2M | $85.6M | ||
| Q1 24 | $12.8M | $82.9M |
总债务AMSCSTL
| Q4 25 | $17.4M | $10.1M | ||
| Q3 25 | $18.2M | $10.0M | ||
| Q2 25 | $19.1M | $10.0M | ||
| Q1 25 | $19.9M | $10.0M | ||
| Q4 24 | $20.4M | $10.0M | ||
| Q3 24 | $14.4M | $10.0M | ||
| Q2 24 | $15.1M | $10.0M | ||
| Q1 24 | $15.6M | $10.0M |
股东权益AMSCSTL
| Q4 25 | $24.0M | $470.9M | ||
| Q3 25 | $24.6M | $467.0M | ||
| Q2 25 | $24.5M | $455.4M | ||
| Q1 25 | $24.6M | $440.3M | ||
| Q4 24 | $25.2M | $455.8M | ||
| Q3 24 | $26.4M | $441.1M | ||
| Q2 24 | $26.5M | $423.9M | ||
| Q1 24 | $22.8M | $402.5M |
总资产AMSCSTL
| Q4 25 | $55.5M | $578.6M | ||
| Q3 25 | $59.6M | $562.8M | ||
| Q2 25 | $63.5M | $544.7M | ||
| Q1 25 | $63.3M | $501.7M | ||
| Q4 24 | $60.2M | $531.2M | ||
| Q3 24 | $63.3M | $514.6M | ||
| Q2 24 | $60.8M | $487.3M | ||
| Q1 24 | $50.1M | $458.5M |
负债/权益比AMSCSTL
| Q4 25 | 0.72× | 0.02× | ||
| Q3 25 | 0.74× | 0.02× | ||
| Q2 25 | 0.78× | 0.02× | ||
| Q1 25 | 0.81× | 0.02× | ||
| Q4 24 | 0.81× | 0.02× | ||
| Q3 24 | 0.54× | 0.02× | ||
| Q2 24 | 0.57× | 0.02× | ||
| Q1 24 | 0.68× | 0.02× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-704.0K | $26.9M |
| 自由现金流经营现金流 - 资本支出 | $-2.7M | $19.7M |
| 自由现金流率自由现金流/营收 | -34.8% | 22.7% |
| 资本支出强度资本支出/营收 | 25.7% | 8.3% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-8.5M | $28.3M |
8季度趋势，按日历期对齐
经营现金流AMSCSTL
| Q4 25 | $-704.0K | $26.9M | ||
| Q3 25 | $1.7M | $22.6M | ||
| Q2 25 | $-372.0K | $20.8M | ||
| Q1 25 | $2.5M | $-6.0M | ||
| Q4 24 | $274.0K | $24.4M | ||
| Q3 24 | $472.0K | $23.3M | ||
| Q2 24 | $1.3M | $24.0M | ||
| Q1 24 | $-1.9M | $-6.8M |
自由现金流AMSCSTL
| Q4 25 | $-2.7M | $19.7M | ||
| Q3 25 | $-2.0M | $7.8M | ||
| Q2 25 | $-2.3M | $11.6M | ||
| Q1 25 | $-1.5M | $-10.8M | ||
| Q4 24 | $-4.4M | $16.8M | ||
| Q3 24 | $-407.0K | $17.0M | ||
| Q2 24 | $70.0K | $18.8M | ||
| Q1 24 | $-3.0M | $-16.0M |
自由现金流率AMSCSTL
| Q4 25 | -34.8% | 22.7% | ||
| Q3 25 | -28.3% | 9.4% | ||
| Q2 25 | -32.1% | 13.4% | ||
| Q1 25 | -24.7% | -12.2% | ||
| Q4 24 | -48.4% | 19.5% | ||
| Q3 24 | -5.8% | 19.8% | ||
| Q2 24 | 1.0% | 21.6% | ||
| Q1 24 | -58.4% | -21.9% |
资本支出强度AMSCSTL
| Q4 25 | 25.7% | 8.3% | ||
| Q3 25 | 51.6% | 17.9% | ||
| Q2 25 | 26.9% | 10.7% | ||
| Q1 25 | 65.7% | 5.4% | ||
| Q4 24 | 51.4% | 8.8% | ||
| Q3 24 | 12.6% | 7.4% | ||
| Q2 24 | 17.2% | 6.0% | ||
| Q1 24 | 22.7% | 12.5% |
现金转化率AMSCSTL
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 4.60× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 10.29× | ||
| Q2 24 | 0.36× | 2.69× | ||
| Q1 24 | -15.67× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMS
| Direct Patient Services | $4.0M | 51% |
| Rental Income From Medical Services | $2.7M | 35% |
| Pbrt Services | $1.2M | 15% |
CSTL
| Dermatologic | $48.6M | 56% |
| Non Dermatologic | $38.4M | 44% |
